[Pharmacoepidemiology of epilepsy].
The lecture presents the history of the pharmacotherapy of epilepsy and analyzes the current situation at the pharmaceutical market related to the appearance of new, high-cost antiepileptic drugs in recent decades. The lecture substantiates the need of pharmacoepidemiology studies for the objective assessment of efficacy, safety and economical impact of new antiepileptics, especially in children, taking into account limited randomized preclinical trials in this group of patients. The lecture describes the role of pharmacoepidemiology in supplementing the findings of randomized controlled trials with new real-life evidence, in quantitative evaluation of adverse reactions, and in discovery of new adverse effects, as well as in the development of cost-effective strategies for rational antiepileptic therapy of children and in the overall improvement of public health economics.